Of the 113 global digital health exits recorded in the first half of 2025, 107 were executed through M&A transactions, whereas a mere 6 were achieved via public listings. This profound shift marks a permanent structural transition from a phase of speculative, venture-backed exuberance to one of pragmatic, highly disciplined growth.

The MedTech M&A landscape in Europe in 2025 has shifted fundamentally, moving away from a strategy of broad asset aggregation to one of selective, high-value and strategically aligned investments. This new era of strategic selectivity is defined by a central thesis: acquirers are placing high-conviction bets on mature, innovative companies that offer a clear path to long-term growth and operational efficiency. The market, despite lingering macroeconomic uncertainties, is demo